文献速递临床试验与 GCP流行病学与生物统计

41周引产与期待治疗至42周:随机试验的系统综述与个体参与者数据荟萃分析

Induction of labour at 41 weeks or expectant management until 42 weeks: A systematic review and an individual participant data meta-analysis of randomised trials.
PubMed 文献 · PLoS Med · 2020-12-08

该系统综述与个体参与者数据荟萃分析纳入3项随机对照试验(n=5,161),其中2项提供个体数据(n=4,561),比较无并发症妊娠41周引产与期待治疗至42周。总体引产降低严重不良围产结局(0.4% vs 1.0%,RR 0.43,95%CI 0.21-0.91),获益仅见于初产妇,经产妇无显著差异,剖宫产率无差异。

要点

  • 41周引产总体降低严重不良围产结局,NNT为175。
  • 获益仅见于初产妇(RR 0.20),经产妇无显著差异。
  • 引产不增加剖宫产率(10.5% vs 10.7%)。

核心结论

  • 总体而言,41周引产较期待治疗至42周改善围产结局且不增加剖宫产率。
  • 获益仅见于初产妇,经产妇死亡与发病率过低未能显示效应。
  • 围产死亡率风险降低幅度仍不确定。

研究设计与样本

  • 系统检索PubMed、Embase、Cochrane Library、CINAHL和PsycINFO(2020年2月21日)比较41周引产与期待治疗至42周的随机对照试验。
  • 从89篇全文文章中识别3项合格随机对照试验(n=5,161),其中2项提供个体参与者数据(n=4,561)。
  • 对无个体数据的试验进行聚合数据荟萃分析;预设亚组分析包括产次、 maternal age和BMI。

主要发现

  • 引产组严重不良围产结局 composite 为0.4%(10/2,281)vs 1.0%(23/2,280),RR 0.43(95%CI 0.21-0.91),p=0.027,RD -57/10,000(95%CI -106/10,000至-8/10,000),I2 0%,NNT 175(95%CI 94-1,267)。
  • 围产死亡:引产组1例(<0.1%)vs 8例(0.4%),Peto OR 0.21(95%CI 0.06-0.78),p=0.019,RD -31/10,000(95%CI -56/10,000至-5/10,000),I2 0%,NNT 326(95%CI 177-2,014)。
  • 新生儿入住监护单元≥4天:1.1%(24/2,280)vs 1.9%(46/2,273),RR 0.52(95%CI 0.32-0.85),p=0.009,RD -97/10,000(95%CI -169/10,000至-26/10,000),I2 0%,NNT 103(95%CI 59-385)。
  • 剖宫产率无差异:10.5% vs 10.7%,RR 0.98(95%CI 0.83-1.16),p=0.81。
  • 初产妇严重不良围产结局:引产组0.3%(4/1,219)vs 1.6%(20/1,264),RR 0.20(95%CI 0.07-0.60),p=0.004,RD -127/10,000(95%CI -204/10,000至-50/10,000),I2 0%,NNT 79(95%CI 49-201);经产妇无显著差异(RR 1.59,95%CI 0.15-17.30,p=0.35)。

临床怎么用

  • 妊娠接近41周的无并发症孕妇应被告知根据产次的风险差异。
  • 初产妇可考虑41周引产以降低严重不良围产结局。
  • 经产妇因事件率低,引产获益不明确,应个体化决策。

局限性

  • 最大纳入试验因安全原因经数据安全监查委员会建议提前终止,可能高估围产死亡率效应。
  • 仅2项随机对照试验符合个体数据荟萃分析条件,严重不良新生儿结局事件少限制评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk of perinatal death and severe neonatal morbidity increases gradually after 41 weeks of pregnancy. Several randomised controlled trials (RCTs) have assessed if induction of labour (IOL) in uncomplicated pregnancies at 41 weeks will improve perinatal outcomes. We performed an individual participant data meta-analysis (IPD-MA) on this subject. METHODS AND FINDINGS: We searched PubMed, Excerpta Medica dataBASE (Embase), The Cochrane Library, Cumulative Index of Nursing and Allied Health Literature (CINAHL), and PsycINFO on February 21, 2020 for RCTs comparing IOL at 41 weeks with expectant management until 42 weeks in women with uncomplicated pregnancies. Individual participant data (IPD) were sought from eligible RCTs. Primary outcome was a composite of severe adverse perinatal outcomes: mortality and severe neonatal morbidity. Additional outcomes included neonatal admission, mode of delivery, perineal lacerations, and postpartum haemorrhage. Prespecified subgroup analyses were conducted for parity (nulliparous/multiparous), maternal age (<35/≥35 years), and body mass index (BMI) (<30/≥30). Aggregate data meta-analysis (MA) was performed to include data from RCTs for which IPD was not available. From 89 full-text articles, we identified three eligible RCTs (n = 5,161), and two contributed with IPD (n = 4,561). Baseline characteristics were similar between the groups regarding age, parity, BMI, and higher level of education. IOL resulted overall in a decrease of severe adverse perinatal outcome (0.4% [10/2,281] versus 1.0% [23/2,280]; relative risk [RR] 0.43 [95% confidence interval [CI] 0.21 to 0.91], p-value 0.027, risk difference [RD] -57/10,000 [95% CI -106/10,000 to -8/10,000], I2 0%). The number needed to treat (NNT) was 175 (95% CI 94 to 1,267). Perinatal deaths occurred in one (<0.1%) versus eight (0.4%) pregnancies (Peto odds ratio [OR] 0.21 [95% CI 0.06 to 0.78], p-value 0.019, RD -31/10,000, [95% CI -56/10,000 to -5/10,000], I2 0%, NNT 326, [95% CI 177 to 2,014]) and admission to a neonatal care unit ≥4 days occurred in 1.1% (24/2,280) versus 1.9% (46/2,273), (RR 0.52 [95% CI 0.32 to 0.85], p-value 0.009, RD -97/10,000 [95% CI -169/10,000 to -26/10,000], I2 0%, NNT 103 [95% CI 59 to 385]). There was no difference in the rate of cesarean delivery (10.5% versus 10.7%; RR 0.98, [95% CI 0.83 to 1.16], p-value 0.81) nor in other important perinatal, delivery, and maternal outcomes. MA on aggregate data showed similar results. Prespecified subgroup analyses for the primary outcome showed a significant difference in the treatment effect (p = 0.01 for interaction) for parity, but not for maternal age or BMI. The risk of severe adverse perinatal outcome was decreased for nulliparous women in the IOL group (0.3% [4/1,219] versus 1.6% [20/1,264]; RR 0.20 [95% CI 0.07 to 0.60], p-value 0.004, RD -127/10,000, [95% CI -204/10,000 to -50/10,000], I2 0%, NNT 79 [95% CI 49 to 201]) but not for multiparous women (0.6% [6/1,219] versus 0.3% [3/1,264]; RR 1.59 [95% CI 0.15 to 17.30], p-value 0.35, RD 27/10,000, [95% CI -29/10,000 to 84/10,000], I2 55%). A limitation of this IPD-MA was the risk of overestimation of the effect on perinatal mortality due to early stopping of the largest included trial for safety reasons after the advice of the Data and Safety Monitoring Board. Furthermore, only two RCTs were eligible for the IPD-MA; thus, the possibility to assess severe adverse neonatal outcomes with few events was limited. CONCLUSIONS: In this study, we found that, overall, IOL at 41 weeks improved perinatal outcome compared with expectant management until 42 weeks without increasing the cesarean delivery rate. This benefit is shown only in nulliparous women, whereas for multiparous women, the incidence of mortality and morbidity was too low to demonstrate any effect. The magnitude of risk reduction of perinatal mortality remains uncertain. Women with pregnancies approaching 41 weeks should be informed on the risk differences according to parity so that they are able to make an informed choice for IOL at 41 weeks or expectant management until 42 weeks. Study Registration: PROSPERO CRD42020163174.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Alkmark M, Keulen JKJ, Kortekaas JC, et al. Induction of labour at 41 weeks or expectant management until 42 weeks: A systematic review and an individual participant data meta-analysis of randomised trials. PLoS Med. 2020. PMID: 33290410. doi:10.1371/journal.pmed.1003436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。